EGFR and neoplasm: Data from the recent EVEREST trial (Evaluation of Various Erbitux Regimens by Means of Skin and Tumor Biopsies), involving patients with no or limited skin reactions, suggest that individualized dose titration based on the occurrence and severity of rash might be used to improve treatment response to EGFR inhibitors102.